• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.铜绿假单胞菌血流感染的死亡率预测因子及抗菌药物耐药性和细菌毒力的影响。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01759-19.
2
Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.铜绿假单胞菌血流感染的毒力基因型和耐药谱对死亡率的影响。
Clin Infect Dis. 2015 Feb 15;60(4):539-48. doi: 10.1093/cid/ciu866. Epub 2014 Nov 6.
3
Clinical and bacterial characteristics of Pseudomonas aeruginosa affecting the outcome of patients with bacteraemic pneumonia.影响菌血症性肺炎患者预后的铜绿假单胞菌的临床和细菌特征。
Int J Antimicrob Agents. 2021 Dec;58(6):106450. doi: 10.1016/j.ijantimicag.2021.106450. Epub 2021 Oct 10.
4
Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.广泛耐药铜绿假单胞菌 235 型高危克隆引起的菌血症:直面完美风暴。
Int J Antimicrob Agents. 2018 Aug;52(2):172-179. doi: 10.1016/j.ijantimicag.2018.03.018. Epub 2018 Apr 3.
5
Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia.成人急性白血病患者中耐药铜绿假单胞菌血流感染的危险因素和结局。
Clin Infect Dis. 2020 Dec 23;71(Suppl 4):S386-S393. doi: 10.1093/cid/ciaa1522.
6
Pseudomonas aeruginosa bloodstream infections in children and adolescents: risk factors associated with carbapenem resistance and mortality.儿童和青少年铜绿假单胞菌血流感染:与碳青霉烯类耐药及死亡率相关的危险因素
J Hosp Infect. 2024 Jul;149:56-64. doi: 10.1016/j.jhin.2024.03.022. Epub 2024 May 10.
7
Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.中性粒细胞减少癌症患者血流感染铜绿假单胞菌所致多药耐药的临床预测模型。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02494-19.
8
Weighting the impact of virulence on the outcome of Pseudomonas aeruginosa bloodstream infections.权衡铜绿假单胞菌血流感染毒力对结局的影响。
Clin Microbiol Infect. 2020 Mar;26(3):351-357. doi: 10.1016/j.cmi.2019.06.034. Epub 2019 Jul 6.
9
Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.多药耐药和适当经验性治疗对铜绿假单胞菌菌血症 30 天死亡率的影响。
Antimicrob Agents Chemother. 2012 Sep;56(9):4833-7. doi: 10.1128/AAC.00750-12. Epub 2012 Jul 2.
10
Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study).中性粒细胞减少症血液病患者铜绿假单胞菌血流感染的真实世界应用头孢他啶/他唑巴坦治疗:一项匹配对照研究(ZENITH 研究)。
Microbiol Spectr. 2022 Jun 29;10(3):e0229221. doi: 10.1128/spectrum.02292-21. Epub 2022 Apr 27.

引用本文的文献

1
Dressing Impregnated with Chlorhexidine and Vancomycin for the Prophylaxis of Central Venous Catheter-Related Infections-A Randomized Trial.含氯己定和万古霉素的敷料预防中心静脉导管相关感染的随机试验
Infect Dis Rep. 2025 Aug 19;17(4):102. doi: 10.3390/idr17040102.
2
Evaluation of FASTinov for rapid antimicrobial susceptibility testing in Pseudomonas aeruginosa.评估FAStinov用于铜绿假单胞菌快速抗菌药物敏感性测试的效果。
Sci Rep. 2025 Aug 5;15(1):28649. doi: 10.1038/s41598-025-12137-w.
3
What we can and cannot see from the surveillance for drug-resistant Pseudomonas aeruginosa-Findings from the evaluation of a surveillance system for multidrug-resistant P. aeruginosa infections in Japan.我们从耐多药铜绿假单胞菌监测中所能看到和看不到的——日本耐多药铜绿假单胞菌感染监测系统评估结果
PLoS One. 2025 Aug 4;20(8):e0329635. doi: 10.1371/journal.pone.0329635. eCollection 2025.
4
Epidemiological and molecular characterisation of carbapenemase-producing Pseudomonas aeruginosa from a tertiary care hospital, India.印度一家三级护理医院产碳青霉烯酶铜绿假单胞菌的流行病学和分子特征分析
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 11. doi: 10.1007/s00210-025-04442-y.
5
Unveiling the research advances of sepsis: pathogenesis, precise intervention and clinical perspective.揭示脓毒症的研究进展:发病机制、精准干预及临床展望
Int J Surg. 2025 Jun 23;111(9):6260-89. doi: 10.1097/JS9.0000000000002668.
6
Multidrug-resistant Pseudomonas aeruginosa in immunocompromised cancer patients: epidemiology, antimicrobial resistance, and virulence factors.免疫功能低下癌症患者中的多重耐药铜绿假单胞菌:流行病学、抗菌药物耐药性及毒力因子
BMC Infect Dis. 2025 Jun 11;25(1):804. doi: 10.1186/s12879-025-11182-0.
7
persistence in the face of antagonism.面对敌意时的坚持。
Front Cell Infect Microbiol. 2025 May 9;15:1569331. doi: 10.3389/fcimb.2025.1569331. eCollection 2025.
8
Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study.新冠疫情后铜绿假单胞菌血流感染中抗菌药物耐药性的下降:一项纵向观察性研究
J Antimicrob Chemother. 2025 Jul 1;80(7):1837-1848. doi: 10.1093/jac/dkaf136.
9
Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study.亚胺培南-西司他丁-瑞来巴坦的真实世界应用:来自一项多中心观察性队列研究的见解
Open Forum Infect Dis. 2025 Feb 26;12(4):ofaf112. doi: 10.1093/ofid/ofaf112. eCollection 2025 Apr.
10
Unveiling the molecular epidemiology of Pseudomonas aeruginosa in lung infections among cystic fibrosis patients in the Brazilian Amazon.揭示巴西亚马逊地区囊性纤维化患者肺部感染中铜绿假单胞菌的分子流行病学。
BMC Microbiol. 2025 Apr 9;25(1):203. doi: 10.1186/s12866-025-03920-w.

本文引用的文献

1
Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.铜绿假单胞菌 O 抗原血清型、耐药谱与高危克隆之间的关联:来自西班牙全国性调查的结果。
J Antimicrob Chemother. 2019 Nov 1;74(11):3217-3220. doi: 10.1093/jac/dkz346.
2
Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology.西班牙全国范围内的铜绿假单胞菌抗菌药物耐药机制和流行病学调查。
J Antimicrob Chemother. 2019 Jul 1;74(7):1825-1835. doi: 10.1093/jac/dkz147.
3
Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.广泛耐药铜绿假单胞菌 235 型高危克隆引起的菌血症:直面完美风暴。
Int J Antimicrob Agents. 2018 Aug;52(2):172-179. doi: 10.1016/j.ijantimicag.2018.03.018. Epub 2018 Apr 3.
4
Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.西班牙广泛耐药铜绿假单胞菌分离株的基因组学和易感性特征。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01589-17. Print 2017 Nov.
5
Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.多重耐药菌引发疾病过程中抗生素耐药性与毒力之间的相互作用
J Infect Dis. 2017 Feb 15;215(suppl_1):S9-S17. doi: 10.1093/infdis/jiw402.
6
Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections.宿主和病原体生物标志物在严重铜绿假单胞菌感染中的作用。
J Infect Dis. 2017 Feb 15;215(suppl_1):S44-S51. doi: 10.1093/infdis/jiw299.
7
Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria.一项为期13年的前瞻性队列研究结果显示,与其他细菌引起的血流感染相比,铜绿假单胞菌引起的血流感染导致的死亡率更高。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02671-16. Print 2017 Jun.
8
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).《脓毒症及脓毒性休克第三次国际共识定义(脓毒症-3)》
JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
9
The increasing threat of Pseudomonas aeruginosa high-risk clones.铜绿假单胞菌高危克隆的威胁日益增加。
Drug Resist Updat. 2015 Jul-Aug;21-22:41-59. doi: 10.1016/j.drup.2015.08.002. Epub 2015 Aug 10.
10
Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology.铜绿假单胞菌和鲍曼不动杆菌中新兴的广谱耐药性:机制与流行病学。
Int J Antimicrob Agents. 2015 Jun;45(6):568-85. doi: 10.1016/j.ijantimicag.2015.03.001. Epub 2015 Mar 24.

铜绿假单胞菌血流感染的死亡率预测因子及抗菌药物耐药性和细菌毒力的影响。

Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.

机构信息

Department of Clinical Microbiology, Instituto de Investigación Hospital 12 de Octubre (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain.

Department of Internal Medicine, Instituto de Investigación Hospital 12 de Octubre (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain.

出版信息

Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01759-19.

DOI:10.1128/AAC.01759-19
PMID:31767719
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6985728/
Abstract

Whether multidrug resistance (MDR) is associated with mortality in patients with bloodstream infections (BSI) remains controversial. Here, we explored the prognostic factors of BSI with emphasis on antimicrobial resistance and virulence. All BSI episodes in a 5-year period were retrospectively analyzed. The impact in early (5-day) and late (30-day) crude mortality of host, antibiotic treatment, and pathogen factors was assessed by multivariate logistic regression analysis. Of 243 episodes, 93 (38.3%) were caused by MDR-PA. Crude 5-day (20%) and 30-day (33%) mortality was more frequent in patients with MDR-PA (34.4% versus 11.3%, < 0.001 and 52.7% versus 21.3%, < 0.001, respectively). Early mortality was associated with neutropenia (adjusted odds ratio [aOR], 9.21; 95% confidence interval [CI], 3.40 to 24.9; < 0.001), increased Pitt score (aOR, 2.42; 95% CI, 1.34 to 4.36; = 0.003), respiratory source (aOR, 3.23; 95% CI,2.01 to 5.16; < 0.001), inadequate empirical therapy (aOR, 4.57; 95% CI, 1.59 to 13.1; = 0.005), shorter time to positivity of blood culture (aOR, 0.88; 95% CI, 0.80 to 0.97; = 0.010), an -positive genotype (aOR, 3.58; 95% CI, 1.31 to 9.79; = 0.013), and the O11 serotype (aOR, 3.64; 95% CI, 1.20 to 11.1; = 0.022). These risk factors were similarly identified for late mortality, along with an MDR phenotype (aOR, 2.18; 95% CI, 1.04 to 4.58; = 0.040). Moreover, the O11 serotype (15.2%, 37/243) was common among MDR (78.4%, 29/37) and -positive (89.2%, 33/37) strains. Besides relevant clinical variables and inadequate empirical therapy, pathogen-related factors such as an MDR phenotype, an -positive genotype, and the O11 serotype adversely affect the outcome of BSI.

摘要

血流感染(BSI)患者的多药耐药(MDR)是否与死亡率相关仍存在争议。在这里,我们探讨了以抗生素耐药性和毒力为重点的 BSI 的预后因素。对 5 年期间的所有 BSI 发作进行回顾性分析。通过多变量逻辑回归分析评估宿主、抗生素治疗和病原体因素对早期(5 天)和晚期(30 天)粗死亡率的影响。在 243 例发作中,93 例(38.3%)由 MDR-PA 引起。MDR-PA 患者的 5 天(20%)和 30 天(33%)死亡率更高(34.4%对 11.3%,<0.001 和 52.7%对 21.3%,<0.001,分别)。早期死亡率与中性粒细胞减少症(调整优势比[OR],9.21;95%置信区间[CI],3.40 至 24.9;<0.001)、Pitt 评分升高(OR,2.42;95%CI,1.34 至 4.36;=0.003)、呼吸道来源(OR,3.23;95%CI,2.01 至 5.16;<0.001)、经验性治疗不足(OR,4.57;95%CI,1.59 至 13.1;=0.005)、血培养阳性时间较短(OR,0.88;95%CI,0.80 至 0.97;=0.010)、-阳性基因型(OR,3.58;95%CI,1.31 至 9.79;=0.013)和 O11 血清型(OR,3.64;95%CI,1.20 至 11.1;=0.022)相关。晚期死亡率也存在这些危险因素,同时还存在 MDR 表型(OR,2.18;95%CI,1.04 至 4.58;=0.040)。此外,O11 血清型(15.2%,37/243)在 MDR(78.4%,29/37)和-阳性(89.2%,33/37)菌株中很常见。除了相关的临床变量和经验性治疗不足外,病原体相关因素,如 MDR 表型、-阳性基因型和 O11 血清型,也会对 BSI 的结果产生不利影响。